Biogen Inc. (BIIB) Social Stream



Biogen Inc. (BIIB): $217.58

-2.06 (-0.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BIIB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Biogen Inc (BIIB) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering BIIB.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-10-28 27 $502 $259 $368.074 $210.65 74.73%
2021-11-19 27 $502 $209 $364.321 $210.65 72.95%
2021-11-30 27 $502 $209 $362.607 $210.65 72.14%
2021-12-08 27 $502 $209 $359.448 $210.65 70.64%
2021-12-09 28 $502 $209 $355.8 $210.65 68.91%
2021-12-21 28 $502 $209 $352.344 $210.65 67.27%
2021-12-22 28 $502 $209 $341.466 $210.65 62.1%
2021-12-23 28 $502 $209 $340.133 $210.65 61.47%
2022-01-07 28 $500 $209 $332.266 $210.65 57.73%
2022-01-13 29 $500 $195 $316.548 $210.65 50.27%
2022-01-14 29 $500 $195 $315.58 $210.65 49.81%
2022-01-18 29 $500 $195 $309.709 $210.65 47.03%
2022-01-28 30 $500 $195 $305.129 $210.65 44.85%
2022-02-02 29 $500 $195 $305.129 $210.65 44.85%
2022-02-04 30 $500 $185 $299.483 $210.65 42.17%
2022-02-08 30 $500 $185 $287.1 $210.65 36.29%
2022-02-15 30 $500 $185 $286.333 $210.65 35.93%
2022-02-25 30 $500 $185 $286.066 $210.65 35.8%
2022-03-03 30 $500 $185 $286.766 $210.65 36.13%
2022-03-08 30 $500 $185 $284.066 $210.65 34.85%
2022-03-11 30 $500 $185 $284.3 $210.65 34.96%
2022-03-28 30 $500 $185 $284.133 $210.65 34.88%
2022-03-31 29 $500 $185 $287 $210.65 36.24%

The Trend in the Analyst Price Target


BIIB's average price target has moved down $32.96 over the prior 22 months.

BIIB reports an average of 30.83% for its upside potential over the past 51 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-07-24 33 647 244.0 407.930 325.40 25.36%
2021-08-07 33 647 279.1 414.420 340.00 21.89%
2022-01-18 30 500 195.0 309.612 233.81 32.42%
2022-02-02 29 500 195.0 305.129 224.96 35.64%
2022-03-31 29 500 185.0 287.000 210.60 36.28%

BIIB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.19 10 3 16 0 0 29

The Trend in the Broker Recommendations


Over the past 20 months, BIIB's average broker recommendation rating improved by 0.49.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In terms of how Biogen Inc fares relative to all US stocks, note that its number of analysts covering the stock is greater than 2591.36% of that group.
  • BIIB has a higher average analyst price target than 2549.76% of Pharmaceutical Products stocks.
  • In the context of stocks in the large market cap category, Biogen Inc's variance in analysts' estimates is lower than -2271.73% of them.
  • In the context of Pharmaceutical Products stocks, Biogen Inc's upside potential (average analyst target price relative to current price) is higher than 577.25% of them.

In the Pharmaceutical Products industry, ARGX, AMGN, and TLRY are the three stocks most similar to Biogen Inc regarding the price target and analyst recommendation information presented here.

What is the outlook for BIIB? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3991 seconds.